Clinical and microbiological factors associated with early patient mortality from methicillin-resistant Staphylococcus aureus bacteremia

被引:16
|
作者
Kim, Tark [1 ]
Chong, Yong Pil [2 ,3 ]
Park, Ki-Ho [4 ]
Bang, Kyung Mi [2 ,3 ]
Park, Su-Jin [2 ,3 ]
Kim, Sung-Han [2 ]
Jeong, Jin-Yong [3 ,5 ]
Lee, Sang-Oh [2 ]
Choi, Sang-Ho [2 ]
Woo, Jun Hee [2 ]
Kim, Yang Soo [2 ,3 ]
机构
[1] Soonchunhyang Univ, Dept Internal Med, Bucheon Hosp, Bucheon, South Korea
[2] Univ Ulsan, Asan Med Ctr, Coll Med, Dept Infect Dis, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea
[3] Univ Ulsan, Ctr Antimicrobial Resistance & Microbial Genet, Seoul, South Korea
[4] Kyung Hee Univ Hosp, Dept Internal Med, Seoul, South Korea
[5] Univ Ulsan, Asan Med Ctr, Coll Med, Asan Inst Life Sci, Seoul, South Korea
来源
KOREAN JOURNAL OF INTERNAL MEDICINE | 2019年 / 34卷 / 01期
关键词
Methicillin-resistant Staphylococcus aureus; Bacteremia; Risk factors; Mortality; BLOOD-STREAM INFECTIONS; MINIMUM INHIBITORY CONCENTRATION; PREDICTIVE FACTORS; HOST-DEFENSE; VANCOMYCIN; FAILURE; EPIDEMIOLOGY; OUTCOMES; STRAINS; IMPACT;
D O I
10.3904/kjim.2016.351
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Aims: Methicillin-resistant Staphylococcus aureus bacteremia (MRS-AB) is a major bloodstream infection with a high mortality rate. Identification of factors associated with early mortality in MRSAB patients would be useful for predicting prognosis and developing new therapeutic options. Methods: A prospective cohort of MRSAB patients was examined between August 2008 and June 2011. Early and late mortality was defined as death within 2 and 28 days of blood culture, respectively. The clinical and microbiological characteristics in the early and late mortality and survival groups were compared. Risk factors associated with severe sepsis or septic shock were also investigated. Results: A total of 385 adult MRSAB patients whose S. aureus isolates were available were enrolled; of these patients, 25 patients (6.5%) and 50 (13%) died early and late, respectively. Compared with both the late-mortality group and the survival group, severe sepsis or septic shock was a statistically significant independent risk factor associated with early mortality. Rapidly or ultimately fatal McCabe and Jackson classification (adjusted odds ratio [aOR], 1.94; 95% confidence interval [CI], 1.25 to 3.02) and pneumonia (aOR, 2.04; 95% CI, 1.03 to 4.02) were independently associated with severe sepsis or septic shock. A vancomycin minimum inhibitory concentration (MIC) >= 1.5 mu g/mL was associated with a reduced incidence of severe sepsis or septic shock (aOR, 0.53; 95% CI, 0.34 to 0.84). Conclusions: Severity of illness seems to be the most important risk factor associated with early mortality in MRSAB. Although vancomycin MIC was not independently associated with early mortality, reduced vancomycin susceptibility appears to be linked to reduced disease severity.
引用
收藏
页码:184 / 194
页数:11
相关论文
共 50 条
  • [21] Patient Factors Associated With Methicillin-Resistant Staphylococcus aureus Septic Arthritis in Children
    Bernstein, Derek T.
    Haruno, Lee S.
    Daram, Shiva
    Dawson, John R.
    Zhang, Wei
    Rosenfeld, Scotttt B.
    ORTHOPEDICS, 2018, 41 (02) : E277 - E282
  • [22] Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia
    Mangili, A
    Bica, I
    Snydman, DR
    Hamera, DH
    CLINICAL INFECTIOUS DISEASES, 2005, 40 (07) : 1058 - 1060
  • [23] A new simplified predictive model for mortality in methicillin-resistant Staphylococcus aureus bacteremia
    Jorgensen, Sarah C. J.
    Lagnf, Abdalhamid M.
    Bhatia, Sahil
    Rybak, Michael J.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2019, 38 (05) : 843 - 850
  • [24] Relationship between mortality and molecular epidemiology of methicillin-resistant Staphylococcus aureus bacteremia
    Shimizu, Masaru
    Mihara, Toshihito
    Ohara, Junya
    Inoue, Keita
    Kinoshita, Mao
    Sawa, Teiji
    PLOS ONE, 2022, 17 (07):
  • [25] A new simplified predictive model for mortality in methicillin-resistant Staphylococcus aureus bacteremia
    Sarah C. J. Jorgensen
    Abdalhamid M. Lagnf
    Sahil Bhatia
    Michael J. Rybak
    European Journal of Clinical Microbiology & Infectious Diseases, 2019, 38 : 843 - 850
  • [26] Ceftaroline for the treatment of methicillin-resistant Staphylococcus aureus bacteremia
    White, Bryin Pinckney
    Barber, Katie E.
    Stover, Kayla R.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2017, 74 (04) : 201 - 208
  • [27] Optimizing therapy for methicillin-resistant Staphylococcus aureus bacteremia
    Cosgrove, Sara E.
    Fowler, Vance G., Jr.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 28 (06) : 624 - 631
  • [28] Evaluation of the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
    Usery, Justin B.
    Vo, Ngan H.
    Finch, Christopher K.
    Cleveland, Kerry O.
    Gelfand, Michael S.
    Self, Timothy H.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2015, 349 (01): : 36 - 41
  • [29] Methicillin-resistant Staphylococcus aureus bacteremia among liver transplant recipients: epidemiology and associated risk factors for morbidity and mortality
    Liu, Taohua
    Zhang, Yuezhong
    Wan, Qiquan
    INFECTION AND DRUG RESISTANCE, 2018, 11 : 647 - 658
  • [30] Methicillin-resistant Staphylococcus aureus bacteremia: The tip of the iceberg
    Pitter, D
    Harbarth, S
    Martin, Y
    Rohner, P
    Henry, N
    Auckenthaler, R
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2000, 21 (06): : 419 - 419